Fusion Antibodies and Isca Diagnostics announce collaboration on antibodies.
Queens University Belfast spin-out Fusion Antibodies has announced plans to collaborate with Isca Diagnostics, commercialising technology from the University of Exeter, on developing antibodies.
Specifically, the two life science firms will be working on the diagnosis and therapy of aspergillosis; a variety of diseases caused by fungal infection. Most humans inhale spores from the Aspergillus genus every day without cause for concern. However, individuals who have become immunocompromised, through drugs or disease, can become susceptible.
The condition can lead to medical complications in the form of a fungus ball developing in the lungs which can cause cough, fever, difficulty in breathing, and death.
Fusion has been developing an antibody to combat aspergillosis, while Isca brings point-of-care tests for the rapid detection of fungal infections to the table.
Richard Buick, chief technical officer of Fusion Antibodies, said: “We are excited to be working with Isca diagnostics on their Aspergillus antibody and confident that Fusion Antibodies CDRx Humanization Platform will deliver high quality humanized antibodies that will accelerate the project into the clinic.”
